MSpharma

PRESCRIBER CHECKLIST
Acknowledgement Form for Prescribing
Ruatine® (Isotretinoin) to Female Patients

The potential for pregnancy must be assessed for all female patients prescribed Ruatine® (Isotretinoin).

A woman has a potential for pregnancy if one of the following applies:

Is a sexually mature woman who:
   1. has not had a hysterectomy or bilateral oophorectomy
   2. is not in a natural postmenopause for a minimum of 24 consecutive months (i.e., menstruated at a certain point in the last 24 consecutive months).

Before initiating Isotretinoin therapy in a female patient, the following checklist must be completed by the Prescriber and kept with the patient notes to document compliance with the Isotretinoin Pregnancy Prevention Programme. After completion, a copy of this document should be given to the patient.

Isotretinoin belongs to the retinoid class of drugs that cause severe birth defects. Foetal exposure to Isotretinoin, even for short periods, presents a high risk of congenital malformations. Isotretinoin is therefore strictly contraindicated in women of childbearing potential, unless all conditions in the Isotretinoin Pregnancy Prevention Programme are fulfilled.

As the prescriber, you must make sure that the risk of serious harm from drug exposed pregnancy is fully understood by all female patients before treating them with Isotretinoin.

This checklist should also be used in all follow-up visits with women of childbearing potential. Please use the patient reminder card to support your discussion with the patient.

Is the patient a woman of childbearing potential?   YES ☐   NO ☐   If 'No' go to section 4
Women of childbearing potential
Review the below statements, explain them to the patient and record confirmation of this and acknowledgment from the patient in this form. If the answer to any of these questions is NO, Isotretinoin must not be prescribed.

	Prescriber confirm: I have explained this to my patient	Patient confirm: I have understood this
Is the patient suffering from a severe form of acne, which is resistant to standard therapies?	☐ YES ☐ No	☐ YES ☐ No

1. Teratogenicity	Prescriber confirm: I have explained this to my patient	Patient confirm: I have understood this
The patient understands that Isotretinoin belongs to a class of drugs (retinoids) known to cause severe birth defects and that they must not get pregnant whilst taking it. Isotretinoin also increases the risk of miscarriage when taken during pregnancy.	☐ YES ☐ No	☐ YES ☐ No

2. Contraception	Prescriber confirm: I have explained this to my patient	Patient confirm: I have understood this
The patient understands that she must consistently and correctly use at least 1 highly effective method of contraception (i.e. a user-independent form such as an intra-uterine device or implant) or 2 complementary methods of birth control (i.e. user-dependent forms such as oral contraceptive and barrier method) before and during treatment.	☐ YES ☐ No	☐ YES ☐ No
The patient understands that the risk persists even after the medication is stopped and that she must not get pregnant within 1 month after stopping treatment.	☐ YES ☐ No	☐ YES ☐ No
The patient has received advice on contraception which is appropriate for her and has committed to using it throughout the risk period.	☐ YES ☐ No	☐ YES ☐ No
The patient is aware of the risk of contraceptive failure.	☐ YES ☐ No	☐ YES ☐ No

3. Pregnancy Testing & Monthly Prescriptions	Prescriber confirm: I have explained this to my patient	Patient confirm: I have understood this
The first prescription for Isotretinoin can only be given after the patient has had one negative medically supervised pregnancy test. This is to make sure she is not already pregnant before starting treatment.	☐ YES ☐ No	☐ YES ☐ No
Patient understands that in order to support regular follow up, including pregnancy testing and monitoring, ideally the prescription should be limited to 30 days.	☐ YES ☐ No	☐ YES ☐ No
Patient understands the need for and agrees to pregnancy testing before, during and after treatment.	☐ YES ☐ No	☐ YES ☐ No

	Prescriber	Patient
Patient understands the need to do a pregnancy test 1 month after stopping treatment because the drug stays in the body for 1 month after the last dose and can damage an unborn baby if pregnancy occurs.	☐ YES ☐ No	☐ YES ☐ No
The contraceptive methods and pregnancy test results were recorded in the patient's medical records.	☐ YES ☐ No	☐ YES ☐ No
The patient knows to contact their doctor if they have unprotected sex, miss their period, become pregnant, or suspect that they have become pregnant during the risk period.	☐ YES ☐ No	☐ YES ☐ No
If pregnancy occurs, treatment must be stopped and the patient should be referred to an expert physician specialised or experienced in teratology for advice.	☐ YES ☐ No	☐ YES ☐ No
The patient has received a reminder card and copy of this form.	☐ YES ☐ No	☐ YES ☐ No

4. Other Precautions	Prescriber confirm: I have explained this to my patient	Patient confirm: I have understood this
Patient understands that Isotretinoin has been prescribed to her only and must not be shared with others.	☐ YES ☐ No	☐ YES ☐ No
Patient understands that she must not donate blood during treatment with Isotretinoin and for one month after discontinuation due to the potential risk to the foetus of a pregnant transfusion recipient.	☐ YES ☐ No	☐ YES ☐ No

Prescriber Signature _

Patient (or guardian if under 18) signature _

Date _

Call for reporting

Pregnancies occurring during treatment and within 1 month following discontinuation of treatment should be reported.

■ Cigalah Group

Sharafiyyah District - Al Yousfia Building
P.O. Box 19435 - Ali Bin Abi Taleb Street, Jeddah, 21435 Saudi Arabia
Tel: +966-12-6148259 - Mob: +966-539455825 - Fax: +966-12-6148458
Email: drug-safety@cigalah.com.sa - moghamdi@cigalah.com.sa

■ The National Pharmacovigilance Centre (NPC) Saudi Food and Drug Authority (SFDA)

SFDA call center: 19999
Toll free phone: 8002490000 - Fax: +966-11-2057662
E-mail: npc.drug@sfda.gov.sa - Website: http://ade.sfda.gov.sa/

References:
1. Ruatine® Leaflet
2. Oral isotretinoin Prescriber Checklist [Internet]. Medicines.org.uk. [cited 9 April 2020].
Available from: https://www.medicines.org.uk/emc/rmm/1445/Document

mSpharma